A 52-year-old male presents with a 3 cm ulceroproliferative lesion on the lateral border of the tongue with cervical lymphadenopathy. Biopsy confirms squamous cell carcinoma. He is deemed fit for chemotherapy. What is the drug of choice for induction chemotherapy in locally advanced oral cavity carcinoma?

Explanation

## Induction Chemotherapy for Locally Advanced Oral Cavity Carcinoma **Key Point:** The triplet regimen of cisplatin + 5-fluorouracil (5-FU) + cetuximab is the standard induction chemotherapy for locally advanced squamous cell carcinoma of the oral cavity, as established by major oncology guidelines and the EXTREME trial paradigm. ### Rationale for TPF (Taxane-Cisplatin-Fluorouracil) vs. PF (Cisplatin-Fluorouracil) vs. Cetuximab-Based Regimens | Regimen | Components | Indication | Response Rate | Key Advantage | |---------|-----------|-----------|---------------|---------------| | **PF (Cisplatin + 5-FU)** | Cisplatin 100 mg/m² + 5-FU 1000 mg/m²/day × 5 days | Standard induction | 60–70% | Cost-effective, well-tolerated | | **TPF (Docetaxel + Cisplatin + 5-FU)** | Docetaxel 75 mg/m² + Cisplatin 75 mg/m² + 5-FU | High-risk locally advanced disease | 70–80% | Superior OS in TAX 323/324 trials | | **Cisplatin + 5-FU + Cetuximab** | Cisplatin + 5-FU + Cetuximab 400 mg/m² loading, then 250 mg/m² weekly | EXTREME trial standard (recurrent/metastatic, extrapolated to locally advanced) | 36% (EXTREME) | EGFR targeting, avoids taxane toxicity | | **Monotherapy (Cisplatin or Paclitaxel)** | Single agent | Palliative or cisplatin-ineligible | 20–30% | Reduced toxicity but inferior outcomes | **High-Yield:** The **cisplatin + 5-FU + cetuximab** triplet is the preferred induction regimen in India and most developing healthcare settings because: 1. It is based on the EXTREME trial, which demonstrated improved overall survival in head and neck cancer. 2. Cetuximab (a monoclonal antibody against EGFR) is increasingly available and cost-effective in India. 3. It avoids the severe hematologic and renal toxicity of taxane-based TPF regimens. 4. It is suitable for patients with borderline renal function or age >65 years. ### Treatment Algorithm for Locally Advanced Oral Cavity Carcinoma ```mermaid flowchart TD A[Locally Advanced OCC]:::outcome --> B{Fit for chemotherapy?}:::decision B -->|Yes| C{Renal function & age?}:::decision C -->|Normal, <65 yrs| D[TPF Induction]:::action C -->|Borderline or >65 yrs| E[Cisplatin + 5-FU + Cetuximab]:::action B -->|No| F[Radiation alone or combined modality]:::action D --> G[Reassess after 2-3 cycles]:::decision E --> G G -->|Response| H[Surgery or Concurrent CRT]:::action G -->|No response| I[Salvage therapy]:::action ``` **Clinical Pearl:** Cetuximab-based induction is particularly favored in resource-limited settings because taxanes (docetaxel, paclitaxel) are expensive and carry higher rates of neutropenic sepsis and neuropathy in Indian populations. **Warning:** Cisplatin monotherapy is inadequate for locally advanced disease; combination chemotherapy is mandatory. Methotrexate + bleomycin is an older regimen rarely used today and is inferior to modern triplet regimens.